Posted by Michael Wonder on 19 Nov 2020
Alnylam receives approval for Oxlumo (lumasiran) in the European Union for the treatment of primary hyperoxaluria type 1 in all age groups
19 November 2020 - Oxlumo is the first therapeutic approved for the treatment of primary hyperoxaluria type 1, and the only therapy proven to lower harmful oxalate levels that drive the progression of primary hyperoxaluria type 1 disease.
Alnylam Pharmaceuticals today announced that the European Commission has granted marketing authorisation for Oxlumo (lumasiran), an RNAi therapeutic, for the treatment of primary hyperoxaluria type 1 in all age groups.
